Liquid pharmaceutical formulations of topiramate
US12109188B1 · kind B1 · utility
0Cited by
3References
20Claims
0Family size
Inventors
Key dates
| Filing date | Mar 24, 2023 |
| Grant date | Oct 8, 2024 |
| Priority date | — |
| Expiry date | Mar 24, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain a therapeutically effective amount of topiramate that is from 50 mg/ml to 100 mg/ml and amounts of polyethylene glycol (“PEG”) 400 and glycerol sufficient to result in a greater than a prior art taught calculated maximum amount of the topiramate being in the solution phase of the formulation, at room temperature.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.